Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Agilent Announces SureSelect XT HS2 RNA Reagent Kit, a Library Prep and Target Enrichment Solution for RNA-Seq


Agilent Technologies Inc. (NYSE: A) today announced the release of the SureSelect XT HS2 RNA Reagent Kit. This solution features a modular design that enables a simple and parallel approach for both RNA and DNA samples, allowing customers to streamline and consolidate their workflow without losing time optimizing different kits for different sample types. It marks the latest development in Agilent’s ongoing effort to improve NGS applications and workflows, leveraging the performance and versatility of XT HS2 chemistry.

“Agilent has innovated library prep and target enrichment for RNA and DNA into a parallel sequencing workflow,” says Kevin Meldrum, vice president, and general manager of Agilent’s Genomics Division. “The new streamlined solution will help simplify the technician’s workday and provides fast turnaround time of only 1–2 days for library preparation regardless of sample type.”

The SureSelect XT HS2 RNA Reagent Kit expands the NGS applications of the XT HS2 chemistry, allowing customers to accurately profile gene expression and detect RNA fusions using low-input FFPE samples. The addition of this kit distinguishes Agilent as the leading vendor in the industry to offer a complete end-to-end NGS sample prep solution from sample QC, library prep and target enrichment, automation, and data analysis, backed by a simple and easy one-stop-shop ordering and support experience.

The kit is anticipated to significantly improve efficiency, especially in labs processing both DNA and RNA samples for NGS applications. “This new solution delivers fast turnaround time so we can spend less time on wet lab work and focus more on results,” says Georges A. Belderbos, head of marketing and sales for NEO New Oncology GmbH. “FFPE compatibility and a parallel workflow to the XT HS2 DNA kit simplified implementation so we could start detecting RNA fusions quickly.”

SureSelect XT HS2 RNA supports 384 unique dual sample indexes (UDIs) and allows customers to multiplex hundreds of samples in one sequencing run without worrying about index hopping. It features molecular barcodes, for more efficient deduplication of sequencing reads and more accurate gene expression analysis. SureSelect XT HS2 RNA may be purchased with Ampure and Streptavidin beads as part of a complete kit.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005282/en/

Agilent Technologies Inc. Stock

€124.40
-0.900%
Agilent Technologies Inc. shows a slight decrease today, losing -€1.140 (-0.900%) compared to yesterday.
Our community is currently high on Agilent Technologies Inc. with 17 Buy predictions and 3 Sell predictions.
With a target price of 133 € there is a slightly positive potential of 6.91% for Agilent Technologies Inc. compared to the current price of 124.4 €.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments